摘要
继发性甲状旁腺功能亢进症是终末期肾脏病患者(特别是血液透析或腹膜透析患者)的常见并发症之一。继发性甲旁亢所导致的血管钙化又是患者发生心血管事件的重要危险因素。引起继发性甲旁亢和血管钙化有多种因素,如何更好地防治继发性甲旁亢、预防由此导致的血管钙化,现已成为广大肾脏病学者研究的热点之一。本文就近年来文献所报道的继发性甲旁亢与血管钙化的相关研究进展作一简述。
Secondary hyperparathyroidism is one of the common complications of patients with end-stage renal disease,especially hemodialysis or peritoneal dialysis patients.Vascular calcification caused by secondary hyperparathyroidism is an important risk factor for cardiovascular events in patients.There are multiple factors that cause secondary hyperparathyroidism and vascular calcification.How to better prevent and treat secondary hyperparathyroidism and prevent vascular calcification caused by this disease has become one of the hot spots for the majority of nephrologists.In this paper,the recent research progress on secondary hyperparathyroidism and vascular calcification reported in the literature is briefly described.
引文
1.Lullo DL,House A,Gorini A,et al.Chronic kidney disease and cardiovascular complications.Heart Failure Reviews,2015,20(3):259-272.
2.Palit S,Kendrick J.Vascular calcification in chronic kidney disease:role of disordered mineral metabolism.Curr Pharm Des,2014,20(37):5829-5833.
3.Miller EO,Schwartz RG.Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe,effective,and well tolerated:Does it matter?J Nucl Cardiol,2017,24(1):119-121.
4.王海燕张路霞,中国慢性肾脏病的现状及挑战——来自中国慢学病性肾脏病流行调查的启示.中华内科杂志,2012,51(7):第497-498页.
5.王海燕张路霞王芳王莉王文科,中国慢性肾脏病患病率的横断面调查.中华内科杂志,2012,51(7):第570页.
6.Malberti F,Marcelli D,Conte F,et al.Parathyroidectomy in patients on renal replacement therapy:an epidemiologic study.J Am Soc Nephrol,2001,12(6):1242-1248.
7.Moldovan D,Racasan S,Kacso IM,et al.Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism.International Urology and Nephrology,2015,47(11):1871-1877.
8.Hirotaka Komaba,Takatoshi Kakuta,Masafumi Fukagawa.Management of secondary hyperparathyroidism:how and why?Clinical and Experimental Nephrology,2017,21(S1):37-45.
9.Quan Yuan,Tadatoshi Sato,Michael Densmore,et al.FGF-23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH.Journal of Bone and Mineral Research,2011,26(9):2026-2035.
10.Gutierrez O,Isakova T,Rhee E,et al.Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.J Am Soc Nephrol,2005,16(7):2205-2215.
11.SinhaMD,Turner C,Dalton RN,et al.Goldsmith.Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5.Nephrol Dial Transplant,2012,27(12):4361-4368.
12.Ohnishi M,Razzaque M S.Osteo-renal cross-talk and phosphate metabolism by the FGF23-Klotho system.Contributions to nephrology,2013,180:1-13.
13.Gutierrez O,Isakova T,Rhee E,et al.Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.J Am Soc Nephrol,2005,16(7):2205-2215.
14.Cozzolino M,Galassi A,Conte F,et al.Treatment of secondary hyperparathyroidism:the clinical utility of etelcalcetide.Ther Clin Risk Manag,2017,13:679-689.
15.Frances C Bachl,Kirsten Ruttenl,Kristyanne Hendriks1,et al.The Paracrine Feedback Loop Between Vitamin D3(1,25(OH)2D3)and PTHrP in Prehypertrophic Chondrocytes.Journal of Cellular Physiology,2014,229(12):1999-2014.
16.Dusso AS,Thadhani R,Slatopolsky E.Vitamin D receptor andanalogs.Seminars in Nephrology,2004,24(1):10-16.
17.Viswanathan G,Sarnak MJ,Tighiouart H,et al.The association of chronic kidney disease complications by albuminuria and glomerular filtration rate:a cross-sectional analysis.Clin Nephrol,2013,80(07):29-39.
18.Moranne O,Froissart M,Rossert J,et al.Timing of onset of CKD-related metabolic complications.J Am Soc Nephrol,2009,20(1):164-71.
19.Bohnert BN,Daniel C,Amann K,et al.Impact of Phosphorus Restriction and Vitamin D-Substitution on Secondary Hyperparathyroidism in a Proteinuric Mouse Model.Kidney and Blood Pressure R,2015,40(2):153-165.
20.Roszko,Kelly L,Ruiye DBi,et al.Autosomal Dominant Hypocalcemia(Hypoparathyroidism)Types 1 and 2.Frontiers in physiology,2016,7:458.
21.Zhang Kun,Gao Jingwei,Chen Jie,et al,An easily ignored contributor to arterial calcification in CKD patients.Am.J.Physiol.Renal Physiol,2016,311(4):F663-F670.
22.Vassalle Cristina,Mazzone Annamaria.Bone loss and vascular calcification:A bi-directional interplay?Vascul Pharmacol,2016.86:77-86.
23.Vulpio C,Bossola M,Magalini SC,et al.Parathyroid-gland ultrasonography in clinical and therapeutic evaluation of renal secondary hyperparathyroidism.La radiologia medica,2013.118(5):707-722.
24.Lee Hye-Jeong,Seo U-Hyoung,Kim Woo-Young,et al.Calciumsensing receptor and apoptosis in parathyroid hyperplasia of patients with secondary hyperparathyroidism.J Int Med Res,2013,41(1):97-105.
25.Bobryshev YV.Editorial:targeting vascular calcification:update.Curr Pharm Des,2014,20(37):5799-5800.
26.Koike Sayo,Yano Shozo,Tanaka Sayuri,et al.Advanced Glycation End-Products Induce Apoptosis of Vascular Smooth Muscle Cells:A Mechanism for Vascular Calcification.Int J Mol Sci,2016,17(12):1567.
27.Gupta A,Winer K,Econs MJ,et al.FGF-23 is elevated by chronic hyperphosphatemia.J Clin Endocrinol Metab,2004,89(9):4489-4492.
28.Melamed ML,Eustace JA,Plantinga L,et al.Changes in serum calcium,phosphate,and PTH and the risk of death in incident dialysis patients:a longitudinal study.Kidney Int,2006,70(2):351-357.
29.Raggi P,Boulay A,Chasan-Taber S,et al.Cardiac calcification in adult hemodialysis patients.A link between end-stage renal disease and cardiovascular disease?J Am Coll Cardiol,2002,39(4):695-701.
30.Azechi T,Sato F,Sudo R,et al.5-aza-2'-Deoxycytidine,a DNA methyltransferase inhibitor,facilitates the inorganic phosphorusinduced mineralization of vascular smooth muscle cells.J Atheroscler Thromb,2014,21(5):463-476.
31.Murshed M,Harmey D,Millan JL,et al.Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone.Genes Dev,2005,19(9):1093-1104.
32.Senatore M,Coppolino G,Papalia T,et al.Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?Ear Rev Med Pharmacol Sci,2011,15(11):1352-1354.
33.魏青.司维拉姆对血液透析患者疗效和终点事件影响的荟萃分析.临床荟萃,2015,30(09):第1008-1012+1017页.
34.Yamada S,Tokumoto M,Tsuruya K,et al.Fetuin-A decrease induced by a low-protein diet enhances vascular calcification in uremic rats with hyperphosphatemia.Am J Physiol Renal Physiol,2015,309(8):F744-F754.
35.Teng M,Wolf M,Ofsthun MN,et al.Activated injectable vitamin D and hemodialysis survival:a historical cohort study.J Am Soc Nephrol,2005,16(4):1115-1125.
36.Yan YC,Qian JQ,Chen N,et al.Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.Clin Nephrol,2014,81(01):20-29.
37.St-Arnaud R,Arabian A,Yu VW,et al.24(S)(OH)2D2normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxy vitamin D-1-hydroxylase(CYP27B1)-deficient mice,an animal model of vitamin D deficiency with secondary hyperparathyroidism.J Endocrinol Invest,2008,31(8):711-717.
38.李艳博,张凌.2016午KDIGO慢性肾脏病骨与矿物质紊乱指南更新意见稿解读.中国实用内科杂志,2016,36(12):1040-1043.
39.Aladren Regidor MJ.Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism(SHPT)in hemodialysis patients.Clin Nephrol,2009,71(2):207-213.
40.Belorusova Anna Y,Martinez Andrea,Gandara Zoila,et al.Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain.Eur J Med Chem,2017,134:86-96.
41.Thadhani RA,Zella JB,Knutson DC,et al.2MD(DP001),a Single Agent in the Management of Hemodialysis Patients:A Randomized Trial.Am J Nephrol,2017,45(1):40-48.
42.Ennis Jennifer L,Worcester Elaine M,Coe Fredric L,et al.Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.Journal of Nephrology,2016,29(1):63-70.
43.Hawley Carmel M,Holt Stephen G.Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism.Nephrology,2017,22(2):47-50.
44.Yoshihiro Tominaga,Akio Katayama,Tetsuhiko Sato,et al.Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients.Nephrology,dialysis,transplantation,2003,18(Suppl.3610):65-70.
45.Shih Ming-Lang,Duh Quan-Yang,Hsieh Chung-Bao,et al.Total parathyroidectomy without autotransplantation for secondary hyperparathyroidism.World Journal of Surgery,2009,33(2):248-254.
46.Tominaga Y,Matsuoka S,Uno N,et al.Removal of autografted parathyroid tissue for recurrent renal hyperparathyroidism in hemodialysis patients.World J Surg,2010,34(6):1312-1317.
47.Lin Ho-Cheng,Chen Chien-Liang,Lin Huey-Shyan,et al.Parathyroidectomy improves cardiovascular outcome in nondiabetic dialysis patients with secondary hyperparathyroidism.Clin Endocrinol,2014,80(4):508-515.
48.Komaba Hirotaka,Taniguchi Masatomo,Wada Atsushi,et al.Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.Kidney Int,2015,88(2):350-359.
49.Bleyer AJ,Burkart J,Piazza M,et al.Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD.Am J Kidney Dis,2005,46(3):464-469.
50.Iwamoto N,Sato N,Nishida M,et al.Low parathyroid hormone levels after parathyroidectomy reduce cardiovascular mortality in chronic hemodialysis patients.Clin Exp Nephrol,2016,20(5):808-814.
51.London GM,Marty C,Marchais SJ,et al.Arterial calcifications and bone histomorphometry in end-stage renal disease.J Am Soc Nephrol,2004,15(7):1943-1951.
52.Merle Emilie,Roth Hubert,London Gerard M,et al.Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients.Kidney Int,2016,89(3):666-674.
53.Leopold JA.Reply:Understanding vascular calcification from an evolutionary approach.Trends Cardiovas Med,2017,27(1):70-71.
